Grantham, Mayo, Van Otterloo & Co (GMO)
CERE

Grantham, Mayo, Van Otterloo & Co (GMO)’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-508,838
Closed -$20.8M – 614
2024
Q2 		$20.8M Buy
+508,838
New +$21.2M 0.07% 187

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s CERE Position: Q3 2024 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 508,838 shares — an estimated $20.8M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $20.8M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 508,838 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $20.8M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $20.8M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2024, filed 13 Nov 2024.